drugset
drugset / Trial / NCT04964557

A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia

NCT04964557 ↗

Phase 2 Completed 411 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate safety, efficacy and tolerability of AZD8233.

Timeline

Start
2021-07-07
Primary completion
2022-07-15
Completion
2022-07-15

Outcome

Met primary endpoint

registry analysis (superiority test); AZD8233 vs Placebo; p <0.001; Mean Difference (Final Values) -62.3 (95% CI -68 to -56.6); ANCOVA NCT04964557 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD8233 Antisense oligonucleotide — Subcutaneous

Indications

hyperlipidemia